Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023)

  • ID: 4463731
  • Report
  • Region: Global
  • 195 pages
  • Azoth Analytics
1 of 5

FEATURED COMPANIES

  • Allergan
  • Eli Lilly
  • Forest laboratories
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE
"Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)"

Executive Summary

A comprehensive research report that analyses the antidepressant drugs market and the drugs market by Class - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics and Novel Agents, the report also assesses the sales of antidepressant drugs by sales channels - Hospital & Clinics, Retail Pharmacies, Others.

A research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antidepressant Drugs Market By Region (North America, Europe, Asia Pacific and Rest of the world) and By Country (U.S., Canada, Germany, United Kingdom, India, Japan China, Brazil, Saudi Arabia) for the historical period of 2013-2017 and forecast period of 2018-2023.

According to the research report, “Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)” global antidepressants market is projected to display a robust growth represented by a CAGR of 3.12 % during 2018 - 2023.

The segment of Selective Serotonin Reuptake Inhibitors (SSRIs) drug class witnessed growth at a noteworthy rate over the past few years and in the forecast period on the back of rising awareness related metal disorders, rising healthcare expenditures along with rising disposable incomes. Amongst the regions, North America accounts for the largest regional share in the global antidepressant drugs market in 2017. Key factors driving the robust growth rate of North America region include rising healthcare expenditure, addition of new drugs, rising disposable incomes, rising number of hospitals and clinics etc.

The report titled “Global Antidepressant Drugs Market - Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)” has covered and analysed the potential of Global Antidepressants Drugs Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global antidepressants drug. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Antidepressants Market, By Value (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antidepressant Drugs Market - Sizing and Growth
  • Analysis By Drugs Class - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective -Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics, Novel Agents
  • Analysis By Sales Channels - Hospital & Clinics, Retail Pharmacies, Others
Regional Markets - North America, Europe, APAC and Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antidepressant Drugs Market - Sizing and Growth
  • Analysis By Drugs Class - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics, Novel Agents
  • Analysis By Sales Channels - Hospital & Clinics, Retail Pharmacies, Others
Country Analysis - U.S., Canada, Germany, United Kingdom, India, Japan China, Brazil, Saudi Arabia (Actual Period: 2013-2017, Forecast Period: 2018-2023)
  • Antidepressant Drugs Market - Sizing and Growth
  • Analysis By Drugs Class - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective -Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics, Novel Agents
Other Report Highlights
  • Market Dynamics - Drivers and Restraints
  • Market Trends
  • Porter Five Force Analysis
  • Policy and Regulatory Landscape
  • Company Analysis - Pfizer, GlaxoSmithKline, Allergan, Forest laboratories, Takeda, Novartis, Eli Lilly
Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan
  • Eli Lilly
  • Forest laboratories
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • MORE
1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Antidepressant Drugs Market Outlook

5. Global Antidepressant Drugs Market: Growth and Forecast
5.1. By Value (2013-2017)
5.2. By Value (2013-2017)

6. Global Antidepressant Drugs Market: By Drugs Class
6.1. Global Antidepressant Drugs Market-By Drugs Class: Breakdown (%)
6.1.1. Global Antidepressant Drugs Market Size and Share, By Drugs, 2017
6.1.2. Global Antidepressant Drugs Market Size and Share, By Drugs, 2023
6.2. Global Selective Serotonin Reuptake Inhibitors Market Overview
6.2.1. By Value (2013-2023)
6.3. Global Serotonin and Norepinephrine Reuptake Inhibitors Market Overview
6.3.1. By Value (2013-2023)
6.4. Global Monoamine Oxidase Inhibitors Market Overview
6.4.1. By Value (2013-2023)
6.5. Global Tricyclic Antidepressant Drugs Market Overview
6.5.1. By Value (2013-2023)
6.6. Global Benzodiazepines Antidepressant Drugs Market Overview
6.6.1. By Value (2013-2023)
6.7. Global Antipsychotics Antidepressant Drugs Market Overview
6.7.1. By Value (2013-2023)
6.8. Global Novel Agents Antidepressant Drugs Market Overview
6.8.1. By Value (2013-2023)
6.9. Global Other Antidepressant Drugs Market Overview
6.9.1. By Value (2013-2023)

7. Global Antidepressant Drugs Market: By Sales Channels
7.1. Global Antidepressant Drugs Market-By Sales Channels: Breakdown (%)
7.1.1. Global Antidepressant Drugs Market Size and Share, By Sales Channels, 2017
7.1.2. Global Antidepressant Drugs Market Size and Share, By Sales Channels, 2023
7.2.Global Antidepressant Drugs Market, By Hospital & Clinics Overview
7.2.1. By Value (2013-2023)
7.3. Global Antidepressant Drugs Market, By Retail Pharmacies Overview
7.3.1. By Value (2013-2023)
7.4. Global Antidepressant Drugs Market, By Others Overview
7.4.1. By Value (2013-2023)

8. Global Antidepressant Drugs Market: Pipeline Analysis

9. Global Antidepressant Drugs Market: Regional Analysis
9.1. Global Antidepressant Drugs Market, By Region: Breakdown (%)
9.1.1. Global Antidepressant Drugs Market Size, By Region, 2017 (%)
9.1.2. Global Antidepressant Drugs Market Size, By Region, 2023 (%)
9.2. Global Antidepressant Drugs Market Size, By Region, 2023 (%)
9.2.1. By Value (2013-2017)
9.2.2. By Value (2018-2023)
9.3. North America Antidepressant Drugs Market: Segment Analysis
9.3.1. North America Antidepressant Drugs Market: By Drug Class
9.3.1.1.North America Antidepressant Drugs Market Size, By Value, 2013-2023
9.3.2. North America Antidepressant Drugs Market: By Sales Channels
9.3.2.1. North America Antidepressant Drugs Market Size, By Value, 2013-2023F
9.4. North America Antidepressant Drugs Market: Country Analysis (U.S. and Canada)
9.4.1. U.S. Antidepressant Drugs Market, By Value (2013-2023)
9.4.1.1. U.S. Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.4.2. Canada Antidepressant Drugs Market, By Value (2013-2023)
9.4.2.1. Canada Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.5. Europe Antidepressant Drugs Market: An Analysis
9.5.1. By Value (2013-2017)
9.5.2. By Value (2018-2023)
9.6. Europe Antidepressant Drugs Market: Segment Analysis
9.6.1. Europe Antidepressant Drugs Market: By Drug Class
9.6.1.1. Europe Antidepressant Drugs Market Size, By Value, 2013-2023
9.6.2. Europe Antidepressant Drugs Market: By Sales Channels
9.6.2.1. Europe Antidepressant Drugs Market Size, By Value, 2013-2023F
9.7. Europe Antidepressant Drugs Market: Country Analysis (U.K., Germany & Rest of Europe)
9.7.1. United Kingdom Antidepressant Drugs Market, By Value (2013-2023)
9.7.1.1. United Kingdom Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.7.2. Germany Antidepressant Drugs Market, By Value (2013-2023)
9.7.2.1. Germany Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.7.3. Rest of Europe Antidepressant Drugs Market, By Value (2013-2023)
9.8. Asia Pacific Antidepressant Drugs Market: An Analysis
9.8.1. By Value (2013-2017)
9.8.2. By Value (2018-2023)
9.9. Asia Pacific Antidepressant Drugs Market: Segment Analysis
9.9.1. Asia Pacific Antidepressant Drugs Market: By Drug Class
9.9.1.1. Asia Pacific Antidepressant Drugs Market Size, By Value, 2013-2023
9.9.2. Asia Pacific Antidepressant Drugs Market: By Sales Channels
9.9.2.1. Asia Pacific Antidepressant Drugs Market Size, By Value, 2013-2023F
9.10. Asia Pacific Antidepressant Drugs Market: Country Analysis (Germany, U.K., & Rest of Europe)
9.10.1. India Antidepressant Drugs Market, By Value (2013-2023)
9.10.1.1. India Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.10.2. China Antidepressant Drugs Market, By Value (2013-2023)
9.10.2.1. China Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.10.3. Japan Antidepressant Drugs Market, By Value (2013-2023)
9.10.3.1. Japan Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.10.4. Rest of Asia Pacific Antidepressant Drugs Market, By Value (2013-2023)
9.11. Rest of World Pacific Antidepressant Drugs Market: An Analysis
9.11.1. By Value (2013-2017)
9.11.2. By Value (2018-2023)
9.12. Rest of World Antidepressant Drugs Market: Segment Analysis
9.12.1. Rest of World Antidepressant Drugs Market: By Drug Class
9.12.1.1. Rest of World Antidepressant Drugs Market Size, By Value, 2013-2023
9.12.2. Rest of World Antidepressant Drugs Market: By Sales Channels
9.12.2.1. Rest of World Antidepressant Drugs Market Size, By Value, 2013-2023F
9.13. Rest of World Antidepressant Drugs Market: Country Analysis (Brazil, Saudi Arabia & Others)
9.13.1. Brazil Antidepressant Drugs Market, By Value (2013-2023)
9.13.1.1. Brazil Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.13.2. Saudi Arabia Antidepressant Drugs Market, By Value (2013-2023)
9.13.2.1. Saudi Arabia Antidepressant Drugs Market, By Drugs Class, By Value (2013-2023)
9.13.3. Others Antidepressant Drugs Market, By Value (2013-2023)

10. Market Dynamics
10.1. Drivers
10.2. Challenges

11. Market Trends

12. Policy and Regulatory Landscape

13. Porter’s Five Forces Analysis - Antidepressant Drugs Market

14. SWOT Analysis - Antidepressant Drugs Market

15. Company Profiles
15.1. Allergan
15.2. Eli Lilly
15.3. Pfizer
15.4. Takeda
15.5. GlaxoSmithKline
15.6. Novartis
15.7. Forest Laboratories

List of Figures
Figure 1: Global Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 2: Global YLDs of Depressive Disorders (2013-2016, %)
Figure 3: Global DALYs of Anxiety Disorders (2013-2016 %)
Figure 4: DALYs due to Mental and Substance Abuse (2016)
Figure 5: World Female Population, 2012-2016 (Million)
Figure 6: World Population 65 Years & Above (% of Total), 2012-2016
Figure 7: Global Unemployment (2016, 2017E, 2018F, (Millions)
Figure 8: Global Health Expenditure Per Capita, By Select Countries, (2016, USD)
Figure 9: Global Health Expenditure Per Capita, (2012-2016, USD Trillion)
Figure 10: Global Antidepressant Drugs Market Size, By Value, 2018-2023 (USD Billion)
Figure 11: Global Antidepressant Drugs Market Size, By Drugs, 2017 (%)
Figure 12: Global Antidepressant Drugs Market Size, By Drugs Class, 2023F (%)
Figure 13: Global Selective Serotonin Reuptake Inhibitors Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 14: Global Selective Serotonin Reuptake Inhibitors Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 15: SSRIs Antidepressants Usage in Different Disorders (%)
Figure 16: Global Serotonin and Norepinephrine Reuptake Inhibitors Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 17: Global Serotonin and Norepinephrine Reuptake Inhibitors Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 18: Global Monoamine Oxidase Inhibitors Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 19: Global Monoamine Oxidase Inhibitors Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 20: Global Tricyclic Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 21: Global Tricyclic Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 22: Global Benzodiazepines Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 23: Global Benzodiazepines Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 24: Global Antipsychotics Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 25: Global Antipsychotics Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 26: Global Novel Agents Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 27: Global Novel Agents Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 28: Global Others Antidepressant Drugs Market, By Value, 2013-2017 (USD Billion)
Figure 29: Global Others Antidepressant Drugs Market, By Value, 2018E-2023F (USD Billion)
Figure 30: Global Antidepressant Drugs Market Size, By Sales Channels, 2017 (%)
Figure 31: Global Antidepressant Drugs Market Size, By Sales Channels, 2023 (%)
Figure 32: Global Antidepressant Drugs Market, By Hospital and Clinics, By Value, 2013-2017 (USD Billion)
Figure 33: Global Antidepressant Drugs Market, By Hospital and Clinics, By Value, 2018E-2023F (USD Billion)
Figure 34: Global Antidepressant Drugs Market, By Retail Pharmacies, By Value, 2013-2017 (USD Billion)
Figure 35: Global Antidepressant Drugs Market, By Retail Pharmacies, By Value, 2018E-2023F (USD Billion)
Figure 36: Global Antidepressant Drugs Market, By Others, By Value, 2013-2017 (USD Billion)
Figure 37: Global Antidepressant Drugs Market, By Others, By Value, 2018E-2023F (USD Billion)
Figure 38: Global Antidepressant Drugs Market Size and Share, By Region, 2017
Figure 39: Global Antidepressant Drugs Market Size and Share, By Region, 2023F
Figure 40: North America Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 41: North America Antidepressant Drugs Market Size, By Value, Forecast, 2018-2023 (USD Billion)
Figure 42: North America Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 43: North America Antidepressant Drugs Market: By Sales Channels, By Value, 2013-2023 (USD Billion)
Figure 44: North America Antidepressant Drugs Market, Country Share, 2017 (% of Total)
Figure 45: North America Antidepressant Drugs Market, Country Share, 2023 (% of Total)
Figure 46: United States Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 47: United States Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 48: United States YLDs by Anxiety Disorders (2013-2016 %)
Figure 49: United States YLDs by Depressive Disorders (2013-2016 %)
Figure 50: United States Prevalence of Different Types of Mental Disorders Among Different Age Group (2016)
Figure 51: Prevalence of Different Types of Mental Disorders Among United States Adults (2016)
Figure 52: Treatment Received Among Adults with Major Depressive Episode (2016)
Figure 53: Per Capita Healthcare Expenditure in United States (2012-2016, USD)
Figure 54: U.S Health Spending by Type of Service or Product, 2016 (%)
Figure 55: United States Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 56: Canada Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 57: Canada Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 58: Canada Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 59: Europe Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 60: Europe Antidepressant Drugs Market Size, By Value, Forecast, 2018-2023 (USD Billion)
Figure 61: Europe Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 62: Europe Antidepressant Drugs Market: By Sales Channels, By Value, 2013-2023 (USD Billion)
Figure 63: Europe Antidepressant Drugs Market, Country Share, 2017 (% of Total)
Figure 64: Europe Antidepressant Drugs Market, Country Share, 2023 (% of Total)
Figure 65: United Kingdom Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 66: United Kingdom Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 67: United Kingdom YLDs by Depressive Disorders (2013-2016 %)
Figure 68: Antidepressant Dispensed in England (2005, 2015, 2016, Million Units)
Figure 69: United Kingdom YLDs by Anxiety Disorders (2013-2016 %)
Figure 70: Per Capita Healthcare Expenditure in United Kingdom (2012-2016, USD)
Figure 71: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 72: United Kingdom Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 73: Germany Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 74: Germany Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 75: Private Healthcare Spending in Germany, US Dollar/capita (2012-2016)
Figure 76: Germany Per Capita Healthcare Expenditure (2012-2016, USD)
Figure 77: Germany YLDs & DALYs by Depressive Disorders (2013-2016 %)
Figure 78: Germany Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 79: Rest of Europe Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 80: Rest of Europe Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 81: Asia Pacific Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 82: Asia Pacific Antidepressant Drugs Market Size, By Value, Forecast, 2018-2023 (USD Billion)
Figure 83: Asia Pacific Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 84: Asia Pacific Antidepressant Drugs Market: By Sales Channels, By Value, 2013-2023 (USD Billion)
Figure 85: Asia Pacific Antidepressant Drugs Market, Country Share, 2017 (% of Total)
Figure 86: Asia Pacific Antidepressant Drugs Market, Country Share, 2023 (% of Total)
Figure 87: India Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 88: India Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 89: Prevalence of Depressive Disorders in India By Age and Sex- (2015-2016)
Figure 90: India Healthcare Expenditure (2012-2016, USD Billion)
Figure 91: India Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 92: China Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 93: China Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 94: China YLDs by Anxiety Disorders (2013-2016 %)
Figure 95: China YLDs & DALYs by Depressive Disorders (2013-2016 %)
Figure 96: China Healthcare Expenditure (2012-2016, USD Billion)
Figure 97: China Population 65 Years & Above (% of Total), 2012-2016
Figure 98: China Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 99: Japan Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 100: Japan Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 101: Japan Per Capita Health Expenditure (2012-2016, USD)
Figure 102: Japan YLDs by Depressive Disorders (2013-2016 %)
Figure 103: Japan Population 65Years & Above (% of Total), 2012-2016
Figure 104: Japan Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 105: Rest of Asia Pacific Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 106: Rest of Asia Pacific Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 107: Rest of World Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 108: Rest of World Antidepressant Drugs Market Size, By Value, Forecast, 2018-2023 (USD Billion)
Figure 109: Rest of World Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 110: Rest of World Antidepressant Drugs Market: By Sales Channels, By Value, 2013-2023 (USD Billion)
Figure 111: Rest of World Antidepressant Drugs Market, Country Share, 2017 (% of Total)
Figure 112: Rest of World Antidepressant Drugs Market, Country Share, 2023 (% of Total)
Figure 113: Brazil Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 114: Brazil Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 115: Brazil Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 116: Saudi Arabia Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 117: Saudi Arabia Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 118: Saudi Arabia Antidepressant Drugs Market: By Drugs Class, By Value, 2013-2023 (USD Billion)
Figure 119: Others Antidepressant Drugs Market Size, By Value, 2013-2017 (USD Billion)
Figure 120: Others Antidepressant Drugs Market Size, By Value, 2018E-2023F (USD Billion)
Figure 121: Pfizer Segmental Breakup, 2016 (%)
Figure 122: Pfizer Sales, By Region, 2016 (%)
Figure 123: Takeda Segmental Break Up
Figure 124: Takeda Geographical Break Up
Figure 125: Novartis Sales, By Segment 2015 (%)
Figure 126: Novartis Sales, By Region, 2015 (%)
Figure 127: Novartis Pharmaceuticals Sales, By Franchise, 2015 (%)

List of Tables
Table A: List of Major Antidepressant Drugs Include in SSRIs Class
Table B: Licenced Indication of SSRIs
Table C: List of Major Antidepressant Drugs Include in SNRIs Class
Table D: List of Major Antidepressant Drugs Include in MAOIs Class
Table E: List of Major Antidepressant Drugs Include in Tricyclic Class
Table F: List of Major Antidepressant Drugs Include in Tetracyclic Class
Table G: List of Major Antidepressant Drugs Include in Benzodiazepines
Table H: List of Major Antidepressant Drugs Include in Antipsychotics
Table I: Antidepressant Drugs Market Analysis, By Drug, Developer, Phase, Indication
Table J: Facts and Figures Driving High Demand of Antidepressants in United States Market
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Pfizer
  • GlaxoSmithKline
  • Allergan
  • Forest laboratories
  • Takeda
  • Novartis
  • Eli Lilly
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll